Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mouth pressure (Pmo), flow rate and mean arterial blood pressure (Pa) data during a single lung volume recruitment manoeuvre in representative subjects.

Published byKaija Lehtinen Modified over 6 years ago

Similar presentations

Presentation on theme: "Mouth pressure (Pmo), flow rate and mean arterial blood pressure (Pa) data during a single lung volume recruitment manoeuvre in representative subjects."— Presentation transcript:

1 Mouth pressure (Pmo), flow rate and mean arterial blood pressure (Pa) data during a single lung volume recruitment manoeuvre in representative subjects in the respiratory muscle weakness (RMW) group in (a), (c), and (e), and in the control group in (b), (d)... Mouth pressure (Pmo), flow rate and mean arterial blood pressure (Pa) data during a single lung volume recruitment manoeuvre in representative subjects in the respiratory muscle weakness (RMW) group in (a), (c), and (e), and in the control group in (b), (d), and (f). Data are presented for a subject in the RMW group with Duchenne muscular dystrophy and a healthy age- and sex-matched subject in the control group. All data presented are raw traces. Yannick Molgat-Seon et al. ERJ Open Res 2017;3: ©2017 by European Respiratory Society

Download ppt "Mouth pressure (Pmo), flow rate and mean arterial blood pressure (Pa) data during a single lung volume recruitment manoeuvre in representative subjects."

Similar presentations

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.
Echocardiography view

Echocardiography view
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Serial imaging while on immunosuppressive therapy (two subjects).

Serial imaging while on immunosuppressive therapy (two subjects).
Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.
Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.
Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.
Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Dried blood spot for therapeutic drug monitoring. a).

Dried blood spot for therapeutic drug monitoring. a).
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
Composition of microbial communities in induced sputa of healthy and mild, moderate, severe or very severe (end-stage) lung disease affected individuals.

Composition of microbial communities in induced sputa of healthy and mild, moderate, severe or very severe (end-stage) lung disease affected individuals.
Comparison of the characteristics at first enrolment for United Network for Organ Sharing (UNOS) patients (n=8315) and virtual patients (n=2 048 784).

Comparison of the characteristics at first enrolment for United Network for Organ Sharing (UNOS) patients (n=8315) and virtual patients (n=2 048 784).
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Survival without tracheostomy

Survival without tracheostomy
Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.

Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.

Similar presentations

Ads by Google